Results
A significant improvement in probability of overall survival (pOS) for
the CoALL-08-09 HR-I patients was noted compared to MRD-matched patients
from the preceding CoALL-07-03 trial in the absence of severe or
persistent treatment-related toxicities. Relapse rate and probability of
event-free survival (pEFS) did not differ significantly between trials.
In patients with IF a stable or improved MRD response after AEP was
observed without severe or persistent treatment-related toxicities.